Clinilabs Inc. has been selected to conduct a Phase I trial of an investigational new drug for insomnia. The study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy subjects and subjects who suffer from primary insomnia. Enrollment is expected to begin in October.   The study will examine dose response on certain defined sleep parameters and wake-time functioning, compared to an FDA-approved insomnia drug and placebo in subjects with insomnia. President and ...